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Introduction 
Evolution of liver transplantation  
Organ transplantation is a treatment modality typically offered to patients with severe 
organ failure. As such, end stage liver disease is not consistent with life, and in the absence of 
other treatment alternatives liver transplantation saves thousands of lives yearly worldwide. In 
Norway 90-100 liver transplantations are now performed each year. 
The first attempt of human liver transplantation was performed by Thomas Starzl et al in 
Denver, Colorado, in 1963.1 Several attempts were undertaken before the first short term success 
with one year survival was performed in 1967. Despite improvements in surgical techniques, the 
procedure remained experimental throughout the 1970s with one year survival rates of about 
25 %.  
Except monozygotic twins, every human and animal is immunologically unique implying 
that organs from other bodies will be recognized as foreign and attempted rejected. As in other 
solid organ transplants, rejection was a major problem during the first years of liver 
transplantation. Patient and graft and patient survival were often restricted by rejection itself, or 
by severe infections as a result of high doses of glucocorticosteroids administered to prevent and 
treat rejections. As such, the introduction of the calcineurin inhibitor cyclosporine by Sir Robert 
Calne in 19782 was a milestone in the field of transplantation medicine. Cyclosporine is a very 
effective drug in preventing rejection and concurrently with growing use the graft survival rates 
increased rapidly. After a consensus conference in 1983 liver transplantation was no longer 
considered an experimental procedure,3 but endorsed as an established treatment option for 
patients with end-stage liver disease. Cyclosporine has later widely been replaced by tacrolimus. 
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Advantages of tacrolimus are better efficacy  enabling administration of corticosteroids at lower 
doses, and lower risk of developing hypertension and renal failure.4;5 Both act as inhibitors of 
calcineurin, a calcium dependent protein phosphatase, and thereby inhibit the formation of 
interleukin (IL) 2 by T-lymphocytes.6;7 Mycophenolate mofetil (MMF), a selective inhibitor of B- 
and T-lymphocyte proliferation, was introduced in the same period as tacrolimus.8 One of the 
major advantages with MMF compared to the calcineurin inhibitors is that MMF is not 
nephrotoxic.   
Along with the development and release of improved immunosuppressive agents, 
continuous improvements in surgical techniques contributed to higher graft- and patient survival 
rates throughout the 1980s. Introduction of venovenous bypass in the early 1990s at the 
University of Pittsburgh, Pennsylvania, represented a major improvement.9;10  However, after 
introducing the piggyback technique enabling surgery without clamping of the inferior caval 
vein,11 venovenous bypass is now considered superfluous in most transplantation centers. Today, 
a number of liver transplantations are performed without transfusion of red blood cells, but is still 
considered one of the most risky procedures performed in hospitals. 12   
Still, end stage liver disease where conventional treatment options have failed is the most 
common indication for liver transplantation. However, and because of the four decade long story 
of medical success, the specter of indications have grown. Most important is that patients 
certainly ending up with an end stage liver disease are transplanted at an earlier time point, but of 
importance is also that patients with e.g. malignancy13 and metabolic disorders like oxalosis14 are 
considered transplant candidates today. Earlier, the transplantation procedure was considered too 
risky for patients who are not at immediate risk of death. An overview of the primary diagnoses 
in 48,218 patients transplanted in Europe from 1999 to 2009 is showed in Table 1.15 
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Surgical procedure in 2012 
Liver transplantation is typically performed as orthotopic liver transplantation (OLT). 
Orthotopic means that the old liver is removed and the new liver is positioned at the same site. 
Although the hepatectomy may be challenging with risk of severe bleeding due to presence of 
(venous) portosystemic shunts and perihepatic tissue adherences, it is usually performed without 
venovenous bypass in an inferior caval vein saving procedure. The new liver, which may be a 
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whole liver or a split segment, is then transplanted. Children typically receive a split segment due 
to limited space in the abdominal cavity, and in such cases the largest split segment can be 
transplanted into an adult in a separate procedure performed simultaneously. Most often the 
piggyback technique is used, i.e. the liver graft with its hepatic veins is sutured to the recipient’s 
inferior caval vein. Thereafter the portal veins from graft and recipient are coupled by an end to 
end anastomosis and the liver is perfused with portal vein blood. The time point of portal vein 
reperfusion represents the end of graft ischemia which starts with clamping of the donor’s aortic 
artery. Severe systematic hemodynamic instability is frequently seen during the first minutes after 
coupling the graft to the recipient’s circulation, and is usually termed reperfusion syndrome.16 
Thereafter, the arterial anastomosis is carried out. Frequently, two and sometimes three hepatic 
arteries must be sutured and in particular in pediatric liver transplantation this may be challenging 
due to small anatomical sizes. However, reperfusion syndrome is rarely seen after hepatic artery 
reperfusion. The biliary anastomosis is made either as choledochocholedochostomy or, in case of 
preexisting biliary disease, as choledochojejunostomy or choledochoduodenostomy. Finally, 1-2 
abdominal drains are established before closure of the abdominal wall. 
Immunosuppression in 2012 
Immunosuppression is most often achieved administering a combination of a 
glucocorticoid, a calcineurin inhibitor, and mycophenolate mofetil. In cases of severe risk of 
rejection, such as redo transplantations and patients with primary sclerosing cholangitis (PSC), or 
preexisting impairment of renal function, an induction treatment with a specific anti IL-2 receptor 
antibody as basiliximab (Simulect®) may be preferred.17  
15 
 
Complications following liver transplantation 
General considerations 
Following a major procedure like liver transplantation with subsequent administration of 
potentially harmful immunosuppressive agents, the patients are at risk of a wide range of 
postoperative complications. Despite considerable therapeutic improvements during the last 
decades, up to 20 % of the transplanted liver grafts are lost within the first year. Importantly, 
most grafts are lost within the first week(s).18 As a consequence, attempts to improve overall graft 
survival rates should imply early detection and adequate treatment of complications, such as 
acute rejection19 and vascular occlusion with subsequent ischemia.20  
Rejection 
Most of the acute rejections are cellular (involving T-lymphocytes) rather than antibody 
mediated and thereby termed acute cellular rejection (ACR).19;21 The reported incidence of ACR 
in the literature is  30-60 %.19  
The condition is suspected when the activity of circulating liver transaminases and/or 
concentration of bilirubin increase, but a biopsy of the graft is required to confirm or refute the 
suspicion.22  However, re-biopsies are frequently required because particularly early biopsies may 
be inconclusive.23 Due to contraindications like coagulopathy or anti-coagulant treatment,22;24 and 
that children in particular are in need of general anesthesia during the procedure, a number of 
patients are given high doses of corticosteroids based on clinical suspicion of cell mediated 
inflammation, rather than a definite diagnosis.25 Most often, rejections are successfully treated 
with intravenously administered pulses of methylprednisolone. However, and more common in 
cases of antibody mediated humoral rejection, plasma exchange may be considered.26   
16 
 
Ischemia 
Vascular complications like hepatic artery thrombosis usually occur during the first 
week(s) after transplantation and represent the most frequent cause for urgent re-transplantation. 
27-29 Clinical signs are often absent since the graft is denervated and cessation of hepatic arterial 
blood flow does not usually affects systemic hemodynamics.  
Ultrasound Doppler is an excellent diagnostic tool detecting vascular complications with 
high levels of sensitivity and specificity when performed by trained radiologists,30;31 but 
continuous monitoring is currently not possible. In the future microprobes may gain clinical 
application.32 In cases were traditional ultrasound Doppler is inconclusive a micro bubble 
contrast medium may be useful, but this application requires specially trained radiologists.33  
Accordingly, transportation of the patient to the radiologic department for a computed 
tomography (CT) angiography examination is often necessary to make the definite diagnosis.34 
Other  
Among a series of possible complications, infections and biliary complications are 
relatively frequent. In the literature the reported incidence of infection is approximately 30 % 35 
and biliary complications occur in approximately 15 %.36 Biliary leakage is usually caused by 
rupture of the biliary anastomosis and may thus be accompanied by peritonitis. Hence, biliary 
leakage and infection often go hand in hand. Bile leakage may be observed in the abdominal 
drain fluid and circulating bilirubin may be increased due to reabsorption. Increased 
concentrations of circulating bilirubin may also indicate presence of cholestasis. Macroscopic 
evident cholestasis may be verified by ultrasound examination, or by endoscopic retrograde 
cholangiography (ERC). ERC also enables therapeutic intervention.37  
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Energy release in glucose metabolism  
 Through several steps including the glycolysis, the Krebs cycle, and the electron transport 
chain, energy, water, and carbon dioxide is released from glucose (C6H12O6) as adenosine 
triphosphate (ATP). ATP is the cells most important immediately available source of energy.  
Each molecule of glucose broken down to pyruvate in the glycolysis implies net release of 
two molecules of ATP. Pyruvate is to some extent reduced to lactate by lactate dehydrogenase 
(LDH), maintaining a stable lactate/pyruvate 
ratio, even under normal aerobic conditions, 
but the gross amount of pyruvate undergoes 
several steps of decarboxylation in the Krebs 
cycle. These steps imply reduction of 
nicotinamide adenine dinucleotide (NAD+) to 
NADH. Assumed that oxygen is available, 
NADH serves as an electron donor in the 
oxidative phosphorylation processes of adenosine diphosphate (ADP) to ATP in the electron 
transport chain located in the inner membrane of the mitochondria. Thereby, additionally 
approximately 36 ATP molecules are released by breakdown of each glucose molecule.  
Rejection 
The energy demand in resting leukocytes is very low, but once activated they need huge 
amounts of energy.  Unlike e.g. hepatocytes and epithelial biliary cells, proliferative cells like T-
lymphocytes cannot fully utilize the theoretical achievable adenosine triphosphate (ATP) 
production in the inner mitochondria. Thus they are first of all dependent on increasing the less 
effective glycolysis.21 Inflammatory processes such as rejection are accompanied by hyperemia 
Figure 1. Overview of how energy is released as ATP in the 
breakdown processes of glucose. 
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and we have a state of increased aerobic glycolysis. The lymphocytes increase their glucose 
uptake rate, glucose is broken down at a 
higher speed, and large amounts of pyruvate 
are produced.  Since the supply of glucose is 
not negatively affected, similar amounts of 
lactate as pyruvate are produced.  Potential 
benefits of monitoring these important 
intermediate metabolites of the glycolysis in 
detecting rejection are unresolved.   
Ischemia 
Ischemia is a state with restricted supply of blood to the tissues. Until the glucose stores 
are depleted, the affected cells can produce ATP by increasing the glycolysis, albeit only 2 mmol 
ATP per mmol of glucose. Since the 
supplies of glucose and oxygen are reduced, 
we have now a state of anaerobic glycolysis. 
Under anaerobic conditions the NADH 
produced in the Krebs cycle cannot be 
oxidized to NAD+ in the electron transport 
chain since this requires oxygen. The toxic 
NADH accumulates and its role as cofactor 
in the reduction of pyruvate to lactate becomes more apparent. Accordingly, pyruvate is 
increasingly converted to lactate and the balance between pyruvate and lactate is moved towards 
lactate.38   
Figure 2. Overview of the glucose metabolism during 
activated lymphocytes during rejection. The shadowed 
area indicated that the lymphocytes cannot fully utilize the 
theoretical possibility for energy production in the inner 
mitochondria. 
Figure 3. Overview of the anaerobic metabolism in 
ischemia. The electron transport chain is shadowed since 
the oxidation of NADH to NAD+ is oxygen dependent. 
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In contrast to muscle cells which can use produce ATP using creatine phosphate and 
thereby survive for 4 – 12 hours under ischemic conditions, hepatocytes cannot survive ischemia 
for more than approximately 30 – 60 minutes.39 The subsequent cell death implies release of 
transaminases to the blood stream, but circulating transaminases increase at a time point when 
graft damage is already evident and in most cases irreversible.40  
Glycerol serves, among other functions such as being an important energy reserve, as 
backbone for the fatty acids in forming the hydrophilic bilayer of phospholipids in the cell 
membranes.41 Cell death therefore implies release of large amounts of glycerol to the surrounding 
tissue caused by phospholipases splitting glycerol from the fatty acids in the phospholipids in the 
cell membrane (Figure 3).  
Inflammation 
Immunological mechanisms are in one way or another involved in almost all pathological 
conditions, and play a major role in rejection and ischemia.  Inflammatory mediators are 
traditionally linked to exogenous stimuli like bacteria, virus or donor tissue, termed pathogen 
associated molecular patterns (PAMP). At present, it is well known that the immune system can 
also become activated by recognition of endogenous molecules, termed alarmins. Alarmins, such 
as high mobility group box 1 (HMBG1) are released upon cell injury due to e.g. ischemia-
reperfusion injury 42-47. Both PAMPs and alarmins lead to a distinct and complex inflammatory 
response, including complement activation with release of the very potent C5a fragment, 
production of cytokines responsible for intercellular signaling, and chemokines inducing 
chemotaxis.  
  
20 
 
Microdialysis 
Microdialysis is a technique which enables monitoring of the tissues and organs of 
interest. Depending on the 
membrane’s pore size, 
metabolic substances (lactate, 
pyruvate, glucose and glycerol) 
and/or mediators of 
inflammation (cytokines, 
chemokines and complement) 
are sampled in a feasible way. 
48 So far, the method’s ability 
to detect brain ischemia is the best validated application. 49;50 In the United States clinical 
application is so far restricted to neurointensive care units as only the brain catheter (CMA 70, 
CMA Microdialysis AB, Stockholm, Sweden) is approved by the Food and Drug Administration 
for clinical use. However, there are more than 2000 clinical reports on microdialysis catheters 
and in Europe the catheters are Conformité Européenne (CE) marked for a wider range of 
indications. Accordingly, we consider the microdialysis method safe although bleeding may 
occur by insertion and theoretically also by removal of the catheters. Like other foreign bodies 
the catheters may get contaminated and thereby be source for bacterial and fungal infections, but 
this is not considered a major problem. The catheters have mainly been used to monitor tissues 
which are at risk of ischemia, 49;51-53 including liver grafts.54-56 A pilot study from Wælgaard in 
our group suggested that also rejection of liver grafts may be detected.56  
  
Figure 4. The figure is reprinted from Paper I with permission from M 
Dialysis AB. 
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Aims of the studies 
General aim of the work 
The overall goal of the presented thesis was to investigate the potential clinical utility of 
monitoring liver transplants by microdialysis catheters. 
 Study I 
The primary objective of this study was to explore whether monitoring substances of 
glucose metabolism in the liver graft by microdialysis catheters detected ischemia and rejection. 
Subsequently, we aimed to explore if this method enabled earlier detection than current clinical 
monitoring practices.   
Study II 
The main objective of this study was to explore the ability of microdialysis catheters to 
sample inflammatory mediators occurring during rejection in liver grafts. Secondary we aimed to 
investigate if the inflammatory response in rejection can be distinguished from the inflammation 
associated with ischemia.  
Study III 
The objective of this report was to investigate microdialysis’ ability to detect ischemia and 
rejection in pediatric liver transplants using the optimal cutoff values determined in Study I. As 
the presence of microdialysis catheters theoretically could interfere with mobilization of the 
patients we also wanted to explore how the catheters were tolerated by the children.  
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Materials and Methods  
Ethical approval 
The study protocol was approved by the Regional Ethical Committee (REK Sør-Øst C). 
Detailed oral and written information was given and a written, informed consent was obtained 
prior to inclusion. Children aged above 10 years and adolescents were given individually adjusted 
oral and written information. 
Definition of clinical endpoints 
Rejection 
Grafts with biopsy confirmed acute cellular rejection. 
Ischemia 
Grafts with vascular occlusion/stenosis or infarction confirmed by ultrasound Doppler 
and/or liver computed tomography (CT). 
Infection and cholestasis 
Since leukocyte activation may imply lactate production, cases of infection, defined as 
elevation of C-reactive protein, concomitant antimicrobial therapy, and focus in or close to the 
graft and occurring while the microdialysis catheter was in the liver were analyzed separately. 
Cases with increments of circulating bilirubin and/or transaminases and histologically confirmed 
cholestasis in the graft were also analyzed separately as the biochemical picture of cholestasis 
may be similar to rejection.  
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Study population 
Study I 
During one year from October 2008 69 patients receiving 73 liver grafts were included. 
Each transplanted graft was defined as one study subject.  Seven patients were given anti-
rejection treatment without histological confirmation of the diagnosis and were excluded from 
analyses as the diagnosis was regarded uncertain in such cases. Thus, in this study we report on 
66 liver transplants.  
 
Figure 5. Overview of the study population in Study I. Seven patients were treated for rejection without biopsy 
confirming the diagnosis and were thus excluded. The darkened boxes represent the included grafts. 
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Study II 
Due to immense costs and high work load related to the laboratory analyses, selected 
grafts from the population included in study I were used in this study. According to the specific 
aims, all grafts with biopsy proven ACR (n=12) and four grafts with vascular occlusion (ischemia) 
were included. In two cases of occluded hepatic artery the grafts were revascularized before we 
were able to collect samples for analyses of inflammatory mediators. Grafts with other cause of 
ischemia than total vascular occlusion (n=3) were not analyzed. The total cohort of grafts in 
which circulating ALT or bilirubin did not increase at any time point while monitored with 
microdialysis were included as references/controls (n=17).  
 
Figure 6: Overview of grafts included in Study II. The darkened boxes are the included grafts; the stapled boxes 
represent excluded grafts. Reprinted from Paper II with permission from John Wiley and Sons. 
 
 
Study III 
Between October 2008 and May 2011 16 patients (11 girls, 5 boys) aged median (range) 
1.9 (0.4 – 15.7) years undergoing totally 20 liver transplantations were included. Eighteen of the 
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transplantations were performed as split liver transplantations. Ten of the grafts (eight recipients) 
were also reported in Study I. 
Microdialysis  
Catheter insertion (Study I, II and III) 
The microdialysis system consists of a small battery driven syringe pump coupled to a 
double tubular catheter with a semi permeable membrane at the tip (Figure 4). The catheters used 
in the present study have an outer diameter of 0.6 mm. Their membranes have 100 kDa pore size, 
and a length of 30 mm. A secure thread is positioned 60 mm from the tip (CMA 65, M Dialysis 
AB, Stockholm, Sweden). At the end of surgery the left abdominal wall was punctured from the 
inside by a hypodermic needle (Sterican® 14G X 3 1/8 “, B. Braun AG, Melsungen, Germany) 
through which the catheters were led. Each catheter entered the abdomen through a separate hole 
and the left side of the abdominal wall was chosen to avoid the access for postoperative 
ultrasound examinations.  The caudal part of each liver lobe was punctured 1-3 cm lateral from 
the falciform ligament in cranial-lateral direction using a splitable introducer (1 mm Ø). Only one 
catheter was used in split transplants. If bleeding was present after removal of the splitable 
introducer, hemostasis was achieved by manual compression and, if necessary, by a clot inducing 
material (Surgicel®, Ethicon, Cornelia GA, USA).  The catheters were secured in the falciform 
ligament or liver capsule by a 6.0 vicryl suture at which the catheter’s secure thread was fixated. 
Finally, a skin secure was performed using a 4.0 thread. The catheters were perfused with 
solution containing dextran and electrolytes  (Plasmodex®, Meda AB, Stockholm, Sweden) at a 
velocity of 1 μl per minute by microinjection pumps (CMA 107, M Dialysis AB, Stockholm, 
Sweden). The perfusion of the catheters was started prior to insertion in the liver tissue. The first 
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microvials were discarded after approximately 30 minutes of liver perfusion to avoid analyzing 
fluid that had not ben perfused through the liver.   
Analyses of metabolic variables (Study I and III) 
Metabolic variables were analyzed bedside every one to two hours after arrival in the 
Intensive Care Unit (ICU). A clinical chemistry analyzer using substrate specific reagents for 
colorimetric measurements of glucose, lactate, pyruvate, and glycerol was used (Iscus, M 
Dialysis AB, Stockholm, Sweden). Lactate/pyruvate ratio was automatically calculated (lactate 
(mM)/pyruvate (μM) x 1000). The catheters were kept in situ for as long as they were able to 
sample microdialysate and then removed transcutaneously.  
Analyses of inflammatory variables (Study II) 
After the patients´ arrival at the ICU, samples were collected and immediately, without 
analyzing metabolic mediators, frozen to -70˚C at following time points: 0, 4, 8, 12 and 24 hours. 
Thereafter, samples were collected and frozen twice daily. Freezing samples at an exact time 
point after graft reperfusion was not feasible, and all reported time points relate to the time point 
of reperfusion of the portal vein. In the cases where two catheters were used, samples from the 
catheter which sampled microdialysate for the longest period were chosen for analyses. The 
complement activation product C5a was analyzed en bloc by Human C5a ELISA Kit II (BD 
Biosciences, San Jose, CA). Following pilot analyses of three patients with rejection using the 
Bio-Plex Human Cytokine 27-Plex Assay (Bio-Rad Laboratories Inc., Hercules, CA), the 
following six mediators were analyzed en bloc: Interleukin-1 receptor antagonist (IL-1ra), C-X-C 
motif chemokine (CXCL) 10, CXCL-8, IL-6, IL-10, and macrophage inflammatory protein 
(MIP)-1β.   
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Statistical analyses 
Statistical analyses were performed with PASW 18.0 (IBM®, Chicago, IL, USA) in all 
studies. Due to the non-normal distribution nature of several of the data, non-parametric 
statistical methods were used when needed. The presented P-values are 2-tailed and P-values < 
0.05 were considered statistically significant.  
Linear mixed models (Study I) 
In order to verify particularly our rejection hypothesis in a mathematical, researcher 
independent way, the initial exploration of the metabolic data were performed by linear mixed 
models. Since the residuals for all investigated variables were normally distributed the data were 
not logarithmically transformed prior to analyses. Residuals are estimates of the statistical errors, 
and in contrast to the classical statistical error using the average of an entire population the 
residual is calculated using the mean of the investigated population. 57 
Except for ischemic events which could clearly be defined by radiological examinations, 
data from other grafts were coded according to the endpoints of the study, i.e. rejection, infection 
and cholestasis. Thus, the time point of occurrence of e.g. rejection was not regarded at this stage 
in the data analyses. We searched for potential group differences, time dependency and possible 
effects of donor, recipient or graft characteristics. The measured metabolic mediators were 
dependent variables. A random effects model was used and model selection was done for each 
variable by choosing the model achieving the lowest Information Criteria. The random effects of 
patient and groups were included in the model. 
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Receiver operating characteristics curves (Study I and II) 
Receiver operating characteristics (ROC)-curves were constructed to explore the ability of 
the investigated mediators to discriminate ischemia and rejection from uneventful conditions 
(Study I and II) and from other pathological conditions (Study II). Area under curve (AUC) was 
calculated and the null hypothesis was AUC = 0.5. The optimal cutoff value for each variable 
was defined as the value closest to the top left corner. 
Mann Whitney U-test (Study I, II and III) 
Mann Whitney U-tests were performed to compare data between groups. 
Wilcoxon Signed Rank test (Study I, II and III) 
Wilcoxon Signed Rank tests were used for repeated measurements. 
Contingency table analyses (Study I and III) 
Values for sensitivity and specificity (Study I and III) were calculated using standard 
formulas for analyses of contingency tables. 
Post-hoc correction of P-values 
For post hoc correction of P-values from tests involving several groups the Bonferroni 
method was used. This is considered a conservative method and implied that in analyses 
involving more than two groups each P-value was divided by the number of tests used to analyze 
the data. 
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Summary of main results 
Study I 
Study population 
Nine liver transplant recipients were diagnosed with ischemia and 12 experienced 
episodes of rejection confirmed by biopsy. In 39 recipients, no major events occurred during the 
period of sampling of metabolic substances (reference group). During the observation period, we 
identified three patients with infection in or close to the graft and three developed cholestasis 
confirmed by graft-biopsy. Two of all investigated patients died; one patient died due to 
complications related to ischemia the first postoperative day and one patient in the reference 
group died due to pulmonary aspergillosis 16 days post transplantation. This patient was included 
in the reference group since her liver function tests were normal for the whole postoperative 
period. 
Of the nine cases of ischemia, five had hepatic artery thrombosis, one graft had 
thrombosis of both the portal vein and hepatic artery, one had stenosis of the right hepatic artery, 
and in two grafts infarction was detected. In 11 of the 12 cases of rejection, circulating ALT 
increased and in nine cases bilirubin increased. All rejections were successfully treated with 
pulses of methylprednisolone.  
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Concentrations of intrahepatic metabolic variables  
Ischemia was detected as increased lactate and lactate/pyruvate-ratio. Rejection was 
detected as simultaneously increased lactate and pyruvate. Glycerol increased exclusively in 
cases of severe ischemia, whereas glucose was similar in all groups (data not shown). The 
concentrations during the different conditions are shown in Figure 7. 
 
Figure 7: Median (interquartile range) concentrations of lactate and pyruvate and calculated lactate/pyruvate 
(LP-ratio) during episodes of acute cellular rejection (ACR, n=12) and ischemia (ISC, n=9) compared to the 
cohort of reference grafts (REF, n=39) with uncomplicated course. The groups were compared by the Mann 
Whitney U-test. The P-values are Bonferroni adjusted for comparison of three groups. Reprinted from Paper I 
with permission from John Wiley and Sons. 
 
Time points of detection of rejection and ischemia  
Lactate measured in arterial blood, increased in only three of the six cases of vascular 
occlusion; in the other three cases arterial lactate remained unchanged.  In the patients where 
arterial lactate increased, these increments were observed 0.3, 6, and 57 hours later than by the 
microdialysis catheters. Accordingly, pathological intrahepatic metabolism was detected by 
microdialysis catheters prior to radiological confirmation of vascular occlusion in all cases. 
Rejection, defined as lactate >2mM and LP-ratio <20 lasting ≥6 hours, was detected median four 
days before ALT (P = 0.02) and bilirubin (P = 0.04) increased. This was median 4 (range = 0-10) 
days before biopsies were performed (P = 0.01).   
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Discrimination of ischemia and rejection  
ROC-curves (Figure 8) revealed that lactate discriminated ischemia with an AUC of 1.00 
(95 % CI, 1.00-1.00) and an optimal cutoff value of 3.0 mM. Likewise, lactate/pyruvate ratio 
discriminated ischemia with an AUC of 0.99 (95 % CI, 0.98-1.00) and an optimal cutoff value of 
20. Lactate discriminated rejection with an AUC of 0.87 (95 % CI, 0.77-0.97) and an optimal 
cutoff value of 2.0 mM. Pyruvate discriminated rejection with an AUC of 0.88 (95 % CI, 0.78-
0.97) and an optimal cutoff value of 170 μM. Using these criteria in contingency table analyses, 
two consecutive positive measurements detected ischemia with 100 % sensitivity and more than 
90 % specificity. Consecutive positive measurements from both liver lobes over a period of at 
least six hours detected rejection with 89 % sensitivity and 83 % specificity.  
 
Figure 8. Receiver operating characteristics (ROC) curves showing how lactate, pyruvate                                   
and lactate/pyruvate (LP)-ratio discriminate ischemia (n=9) and rejection. Reprinted                                         
from Paper I with permission from John Wiley and Sons. 
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Study II 
Initial concentrations of inflammatory variables 
From initially relatively high concentrations, there were time dependent decrements of 
C5a, IL-1ra, IL-6, IL-10 and MIP-1β after graft reperfusion (P < 0.001 for all analyses), whereas 
CXCL-8 and CXCL-10 decreased non-significantly. No differences in any of the investigated 
periods were found between the reference group and the grafts that later developed rejection. 
Rejection 
The concentrations of CXCL-10 increased in both the rejection- and the reference group, 
but it increased significantly earlier and to higher 
values in the rejection group, reaching statistically 
significant differences at day 3 (P = 0.05) and at 
day 4 (P = 0.02), i.e. in samples collected before 
any patient had been given anti-rejection treatment.  
After the initial obligatory peak in ALT following 
graft reperfusion, increments of CXCL-10 were observed during a period of physiological 
decrease in transaminases. Increments of more than 100 % were observed after median 2.2 (range 
= 1.2-3.8) days. This was 1.7 days before any increment in ALT (P=0.02), and 5.2 days before 
bilirubin increased with ≥ 25 % (P = 0.008).  
The peak concentrations of CXCL-10 were significantly higher in the rejection group as 
compared to both the reference group (P = 0.008) and the ischemia group (P=0.004). In the latter 
group, no increase in CXCL-10 was detected. The peak concentrations of IL-6 and CXCL-8 were 
Figure 9. The course of intrahepatic CXCL-10 
compared to circulating ALT in 12 grafts with acute 
cellular rejection  
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also higher in the rejection- as compared to the control cohort, but the differences were not 
statistically significant.  
Ischemia 
The peak concentrations of C5a, CXCL-8 and IL-6 were significantly higher in grafts 
with ischemia as compared to the controls. C5a was the only mediator that was significantly 
higher in the ischemia group than in the rejection group (P=0.008).   
 
Figure 10: Peak concentrations of CXCL-10 and C5a in rejection (ACR), ischemia (ISC) and references (REF). 
Reprinted from Paper II with permission from John Wiley and Sons. 
 
 
Discrimination abilities 
C5a discriminated ischemia from controls with an AUC of 0.96 (95 % CI, 0.87-1.00) (P = 
0.005) and from ACR with an AUC of 0.88 (95 % CI, 0.69-1.00) (P = 0.03). CXCL-8, IL-1ra and 
IL-6 also discriminated well between ischemia and controls, but not as well as C5a. 
CXCL-10 discriminated rejection from controls with an AUC of 0.81 (95 % CI, 0.65-0.97) 
(P = 0.005) and from ischemia with an AUC of 1.00 (95 % CI, 1.00-1.00) (P = 0.004).  
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Figure 11: ROC curves depicting how CXCL-10 and C5a discriminate rejection and ischemia from reference 
grafts. Reprinted from Paper II with permission from John Wiley and Sons. 
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Study III 
Study population 
Of the 20 investigated liver grafts, ischemic vascular complications were detected in six, 
and rejection was proven by histology in eight. Complications other than ischemia and rejection 
occurred in three grafts; infection was detected in one, one had biopsy proven cholestasis, and 
one had primary non function (PNF). One of the sixteen recipients died due to ischemic graft 
complications.  
Sensitivity and specificity in detecting rejection and ischemia 
Using the criteria lactate > 3.0 mM and LP-ratio > 
20 the intrahepatic microdialysis catheters detected 
ischemia with 100 % sensitivity. However, when 
requiring only single time point measurements the 
specificity was as low as 57 %. When requiring two or 
three consecutive positive measurements, only one graft 
with rejection and one with cholestasis (Figure 12) were 
misjudged as ischemia and the value for specificity was 
86 %. 
Using the criteria lactate > 2.0 mM and LP-ratio < 20, single time point measurements 
detected rejection with 100 % sensitivity, but with 0 % specificity. Requiring consecutive 
positive measurements throughout a period of six hours, one graft which displayed rejection 
values lasting just above five hours was coded as rejection and the sensitivity was 88 %. 
Rejection was falsely detected in six grafts and the specificity was thus 45 %. However, in five of 
Figure 12. This patient had a typical rejection 
pattern of the lactate curve, but the  biopsy 
revealed intracanalicular cholestasis. Reprinted 
from Paper III with permission from John 
Wiley and Sons. 
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these cases the clinical- picture and context ruled out rejection as a possible diagnosis. Two were 
in the period of metabolic normalization after already confirmed occluded hepatic artery, two had 
severe peritonitis and abdominal pain 
due to spontaneous perforation of the 
duodenum and leakage from the 
choledochojejunostomy respectively, 
and the last case was in a graft with 
primary non function (PNF) (Figure 
13). When not considering rejection in 
these grafts, the specificity was 83 %. 
One episode of histologically proven 
intracanalicular cholestasis (RAI 1) (Figure 12) could not be ruled out as possible rejection and 
was thus classified “true false positive rejection”.  The results did not change when increasing the 
requirement for consecutive positive measurements to 12 hours, but further increment resulted in 
a decrease in sensitivity.  
Time point of detection of rejection and ischemia in pediatric transplants  
In general, the results from Study I were confirmed in this smaller series of pediatric liver 
transplants. Ischemia was detected close to real time. In one case only intrahepatic, not arterial, 
lactate increased at the time point of thrombosis of the hepatic artery (Figure 14). In another case, 
microdialysis catheters correctly displayed normal metabolism whereas ultrasound Doppler 
falsely suggested an occluded hepatic artery. As in Study I, rejection was detected before 
circulating ALT or bilirubin increased, and before biopsy was performed.  
Figure 13. Graft with primary non function due to prolonged 
ischemia. Increased lactate with stable lactate/pyruvate-ratio (LP-
ratio). Glycerol was increased as sign of ongoing necrosis. 
Reprinted from Paper III with permission from John Wiley and 
Sons. 
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Feasibility, complications and acceptance of microdialysis catheters  
Minor bleeding occurred by insertion of two catheters and was easily handled by manual 
compression and Surgicel®. Significant bleeding was not registered at the time of removal of any 
catheter despite 15 of 20 cases receiving low molecular weight heparin (LMWH) and/or acetyl 
salicylic acid (ASA).  No episodes of infection could be related to the catheters. Microdialysate 
from the liver was sampled for median 10 (range = 1 – 28) days and no differences were found 
between children younger and older than two years in terms of catheter durability. The parents of 
two patients asked for withdrawal of the catheter after 12 and 28 days respectively as they 
perceived the many measurements as a strain to the children who both were fully mobilized and 
doing well. All other patients tolerated and kept their catheters until they were removed because 
of malfunctioning (n=13), re-transplantation (n=4) or re-laparotomy (n=1). No patients were 
immobilized because of the catheters.  
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Discussion 
General considerations 
According to our knowledge, each of the present studies are the largest of its kind 
worldwide.  In Study I, the largest of the three studies including 66 liver transplants, we showed 
that rejection and ischemia may be detected bedside several days before current standard methods. 
In Study II we found a potentially specific biomarker of rejection. Despite Study III being the 
smallest of the three studies, it was performed in the very important and vulnerable group of 
pediatric transplants and is likely to have most immediate clinical impact of the three studies. 
Pathophysiology 
Metabolic variables 
Simplified overviews of the intermediate metabolism in normal conditions, rejection, and 
ischemia are shown in Figures 1 - 3. We consider the simultaneous measurements of lactate and 
pyruvate enabling distinction between aerobic and anaerobic glycolysis of immense importance. 
Contrary to lactate, pyruvate is a more unstable metabolite sensitive to storage time and 
conditions. Pyruvate is thus not a routine variable in a clinical setting. The bedside approach of 
the microdialysis system enables pyruvate measurements in a feasible way and is important for 
the accuracy of diagnostics.  
With reduced oxygen supply as in ischemia the condition is dominated by anaerobic 
glycolysis; NADH, a cofactor to the enzyme LDH, is increased and the balance between pyruvate 
and lactate is shifted towards lactate.38 Thus, the lactate/pyruvate-ratio increases in anaerobic 
glycolysis/ischemia. In the present material pyruvate decreased only in the most severe cases of 
ischemia as e.g. the case of combined hepatic artery- and portal vein thrombosis. Mix of blood 
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from intact vessel systems (hepatic artery or portal vein) with normal contents of glucose and 
oxygen is likely to explain this observation.  
The simultaneous increments of lactate and pyruvate with stable lactate/pyruvate ratio in 
rejection most likely reflect an increased aerobic glycolysis due to lymphocyte-activation.21 
Being aware that we did not measure intrahepatic concentrations of transaminases or bilirubin, 
this statement is supported by detection of significantly increased metabolism several days before 
the traditional markers of cell death or dysfunction increased in blood.   
An increased energy demand due to activation of neutrophil granulocytes is likely to 
explain the observed hypermetabolism associated with infection, apparent as increased lactate 
and pyruvate. In infection, lactate is also released by the oxidative burst mechanism involved in 
bacterial killing,58 and a somewhat higher lactate/pyruvate ratio would be expected with infection 
than in rejection. However, the restricted number of infectious cases in the present material does 
not allow any conclusion to be drawn regarding expected levels of lactate/pyruvate ratio in 
infection. Accordingly, infection should be considered a differential diagnosis to rejection in 
cases where the microdialysate reveals hypermetabolism. Interestingly, no intrahepatic changes 
were found in the case of severe peritonitis suggesting that the liver graft was not infected in this 
case. However, an additional intraperitoneal microdialysis catheter would probably have detected 
the case of peritonitis as reported by others.59-61 Studies aiming to explore the clinical utility of 
intraperitoneal microdialysis positioned between the loops of the small intestine are ongoing and 
may provide valuable experience, in particular in monitoring vulnerable groups of postoperative 
immunosuppressed patients. 
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In one case of canalicular cholestasis (Figure 12) we observed an increased metabolism, 
similar to the hypermetabolism observed in rejection. Cholestasis, with intrahepatic bile duct 
pressure exceeding the capillary pressure, might explain the metabolic condition,62 but absence of 
cholestasis by ultrasound investigation contradicts this explanation. Bilirubin’s powerful 
uncoupling effect on oxidative phosphorylation may be an alternative explanation.63-66 The 
patient was administered 10 mg/kg methylprednisolone intravenously and recovered 
spontaneously. We therefore consider immunological mechanisms possible although not revealed 
by the histo-pathological examination of the biopsy. 
Inflammatory variables 
Despite CXCL-10 being produced by a variety of cells like mononuclear cells, activated 
stellate cells, endothelial cells, and hepatocytes, various reports indicate that it possibly is a 
specific marker of rejection of liver grafts,67-70 as well as of other solid organ transplants.71-75 
CXCL-10 expression is induced by γ-interferon and contributes via stimulation of its receptor 
CXCR3 to migration of T-lymphocytes into the inflamed tissue.67-70;76 Thus, γ-interferon and 
CXCL-10 may be considered early mediators predominantly of the cell mediated, adaptive 
immune system. Our results support that CXCL-10 may be less dependent from the innate than 
the adaptive immune system; it did not increase in ischemia and seemed independent of the 
ischemia/reperfusion injury. A biological explanation to why CXCL-10 is increased in rejection, 
and not ischemia, may be that the precursor γ-interferon probably is independent from 
complement activation.77;78 The complement system mainly represents the innate immune system 
and the biologically highly potent activation product C5a is induced by activation through all 
initial activation pathways. It has a number of effector functions and is e.g. a powerful chemo 
attractant causing accumulation of neutrophil granulocytes and an important inducer of 
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inflammation.79;80 Our data support studies showing that the complement system plays a key role 
in the ischemia/reperfusion injury.44;81 In contrast to C5a, IL-1ra has potent anti-inflammatory 
activities.82  Interestingly, these two inflammatory mediators, which counteract each other, 
closely reflected ischemia/reperfusion, indicating that the inflammatory network functions to 
balance the detrimental effects in this condition. CXCL-8, a member of the CXC-chemokine 
family,83 and IL-6,84 a pro-inflammatory cytokine, increased with ischemia and a positive trend 
was detected also with rejection. This indicates that these mediators are expressed by a general 
activation of the immune system and not specifically by the adaptive (cell mediated) or innate 
immune system. Consequently, neither IL-6 nor CXCL-8 seems to be attractive candidates in the 
search for specific markers of rejection.  
The current study (Study II) using a derived cohort of transplanted patients as “controls” 
(discussed in Limitations), does not formally answer whether the somewhat increased levels of 
CXCL-10 in the reference group represent cell mediated inflammation or constitute a part of the 
normal course after liver transplantation. Some degree of alloreactivity after liver transplantation 
is probably common and/or inevitable, and can be transient. Coinciding minor discharges of 
transaminases or bilirubin may not always be detected in peripheral blood samples, or the 
increases might not be high enough to justify a liver biopsy. Contrary to the study performed by 
Wælgaard et al, 56 C5a did not increase with rejection (Study II). This may be due to a more 
complicated course of the recipients in the former study; two were critically ill prior to 
transplantation and were treated with the molecular adsorbent recirculating system (MARS) and 
one of these had several bowel perforations needing surgical corrections. The third graft had, in 
addition to rejection and stenosis of the choledochus anastomosis, also evidence of vascular graft 
ischemia. 
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Clinical application 
Metabolic variables 
The results suggest that bedside sampling of metabolic mediators using microdialysis 
catheters may be used to detect episodes of ischemia and rejection in liver grafts and that these 
conditions may be identified earlier than by current standards of monitoring and care. The 
method’s ability to detect ischemia and thus alert for possible vessel occlusion is particularly 
important as prolonged ischemia is detrimental for the graft. Consequently, an early detection by 
microdialysis may be graft saving and improve patient survival. The levels of sensitivity and 
specificity of which rejection were detected indicate that this method might also be a useful 
clinical tool in cases of suspected allograft rejection. Thus, this method might act as an alert to 
carry out a biopsy for verification, particularly in the early stage of rejection.  
As indicated in this work and reported in the literature particularly vascular complications 
occur more frequently in the pediatric- as compared to the adult population.85;86 As a 
consequence of the promising results in Study I and III microdialysis is now implemented as part 
of the standard monitoring and care of pediatric liver transplants in our hospital. Slightly 
modified optimal cutoff values (lactate >2.6 mM and LP-ratio > 20) detected in study I and 
explored in Study III are used as an alert to carry out Doppler ultrasound examination which is 
performed after two consecutive positive measurements, the second one analyzed 30 min after 
the first. As the specificity in detecting ischemia was as high as 86 % (Study I) and 83 % (Study 
III) we expect that the number of negative ultrasound Doppler examinations will be acceptable, 
but this will be a question for exploration of future data. 
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When considering using microdialysis in diagnosing rejection, the varying sensitivity and 
specificity depending on the number of repeated measurements should be considered; relying on 
single time point measurements in making decisions about initiating anti-rejection therapy would 
imply that a number of patients would unnecessarily be administered potentially harmful high 
doses of corticosteroids. By requiring consecutive positive measurements for six hours before 
initiating anti-rejection therapy, clinically acceptable levels of both sensitivity and specificity 
were achieved. However, as shown in Study III, the microdialysis data should be assessed 
together with the clinical context and patient condition before making decisions regarding 
performing biopsies, or initiating anti-rejection treatment in cases of contraindications to 
biopsies.22   As stated earlier in this discussion, particularly infection should be considered an 
important differential diagnosis to rejection.  
Inflammatory variables 
Having detected CXCL-10 as a potentially specific marker of rejection in liver grafts is 
most likely the most important finding in Study II. If confirmed in larger studies, and at other 
centers than ours, CXCL-10 might turn out to be an important additional marker to the metabolic 
variables. The absence of C5a in in a microdialysate sample with high concentration of CXCL-10 
(and lactate and pyruvate) would support the presence of rejection.  
As opposed to metabolic mediators which are analyzed bedside relatively cheap and 
feasible, analyzing inflammatory variables is still time and cost consuming laboratory work. Thus, 
both further research and technical development of a fast track analysis kit is needed before e.g. 
CXCL-10 and C5a can be introduced in clinical practice. 
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Feasibility, complications of and acceptance of microdialysis catheters 
More than 2000 clinical microdialysis studies, including gastrointestinal studies, have so 
far been published. The kits for analyzing the reported metabolic variables lactate, pyruvate, 
glucose, and glycerol are commercially available. The equipment used in the current studies is 
Conformité Européenne (CE)-marked, also for livers. Thus, the method may be implemented in 
clinical practice, including liver grafts, in most European countries. In the United States, however, 
only the brain catheter (CMA 71, M Dialysis AB, Stockholm, Sweden) is so far approved by the 
Food and Drug Administration for clinical use. Accordingly, monitoring liver transplants in the 
United States at this stage can only be done in a clinical research setting approved by the 
Institutional Review Board.   
Microdialysis catheters were inserted in 83 liver grafts in the present studies. We had no 
severe complications related to the catheters. By introducing the splitable needle, some episodes 
of minor bleeding occurred that were easily handled by manual compression and a common 
hemostatic agent. Accordingly, this work suggests that microdialysis safely can be used in liver 
transplants. 
Significance of early detection of complications 
Rejection 
Although there is no general agreement regarding the significance of initiating anti-
rejection treatment at an early time point19;87 we argue that early treatment of rejection is 
important. It is well known that hepatocytes are able to regenerate.88 However, hepatocytes are 
not the main targets in the course of rejection. Sinusoidal endothelial cells, bile ducts and small 
intrahepatic arteries are more affected and these do not have the same ability as hepatocytes to 
45 
 
regenerate.87 As the blood flow in the portal vein is diminished with rejection, the risk for portal 
vein occlusion is increased.89Importantly, specific patient populations undergoing liver 
transplantation have distinct postoperative profiles of complications. Patients with primary 
sclerosing cholangitis (PSC) have a higher incidence of both acute and chronic rejection. In these 
patients, acute rejection is associated with higher incidence of chronic rejection and relapse of 
PSC in the graft which again is associated with decreased long term outcome.90 In the large 
population of patients transplanted for hepatitis C virus (HCV) cirrhosis, anti-rejection treatment 
with intravenous corticosteroids have been reported to cause massive viral replication and thus 
recurrence of the disease.91 As a consequence, it is theoretically conceivable that early detection 
of rejection followed by tailored treatment regimens guided by continuous microdialysis 
monitoring to establish the lowest effective dose of immunosuppression would be beneficial in 
these patients. Individualized regimens could theoretically also be advantageous in patients 
infected with Epstein Barr virus (EBV) and in patients already diagnosed with malignancy. In 
these patients, aggressive anti-rejection treatment is associated with higher incidence of post-
transplant lymphoproliferative disease 92 and immunosuppressive medication may trigger growth 
of malignant cells. 93Accordingly, patients with PSC, HCV-cirrhosis, EBV-infection, and 
malignancy may all represent subgroups of patients in which close intrahepatic monitoring might 
be particularly useful.  
Ischemia 
Study I and II show that early detection of potentially reversible ischemic conditions may 
be detected at a very early time point with the microdialysis method. Compared to rejection, it is 
generally agreed upon that early detection of vascular occlusions is of immense importance to be 
able to intervene before irreversible graft failure has occurred to possibly save the graft.94  
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Importantly, we have not shown that the patients actually benefit from having their ischemic 
complications detected at an early time point and this will be a question for future studies. 
Infection 
Infectious complications are severe and common following liver transplantation. 35 It is 
shown that early detection and treatment of severe infections is important to improve the survival 
rates in a general population.95 We consider it conceivable that the vulnerable group of liver 
transplanted patients may benefit from early detection and subsequent treatment of infectious 
complications, and we consider exploring the role of microdialysis for this indication of 
particular importance. 
 
Limitations of the work 
The design in all studies can be characterized as open labeled, prospective, observational 
and non-interventional. The hypotheses were known by the staff treating and nursing the patients 
and by the patients. The potential benefit of early detection of ischemic vascular complications 
would make a blinding ethically difficult. We had no instructions regarding observed 
hypermetabolism and suspected rejection, but strongly assume that the microdialysis data were 
taken into consideration when making decisions regarding performing biopsies or initiating 
treatment without biopsies. In fact, seven patients were given anti-rejection treatment without 
biopsy confirming or refuting the suspicion and thus forcing us to exclude these grafts from data 
analyses. This may have influenced the reported values for sensitivity and specificity and was the 
reason for not reporting positive and negative predictive values. Implementing biopsies in the 
study protocol would most likely have secured a better validation of the data, but protocol 
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biopsies of liver grafts are controversial and abandoned in most centers. 96 As children are in need 
of general anesthesia to enable biopsy, implementing biopsies in the study protocol would imply 
an unfortunate higher level of invasiveness of the study. We assume that in particular the number 
of included children would have been substantially reduced. Reducing the fraction of investigated 
liver grafts in certain diagnostic groups would certainly have impact on the values for sensitivity 
and specificity.  
All studies were performed without a formal control group. The presented groups 
including the reference group(s) are better described as derived cohorts rather than true controls. 
An imaginable control group would have been a group of patients undergoing liver surgery other 
than transplantation, e.g. liver resection. This would undoubtedly be a group of patients without 
any possible risk of rejection and thereby be interesting subjects for comparison of the role of 
CXCL-10 after transplantation. On the other hand, implementing a group of patients in an 
invasive study solely for the purpose of serving as controls would raise ethical concerns. From 
our point of view, such a study design is appealing, but probably more suitable and applicable in 
a laboratory setting.  
The studies were not primarily designed to neither detect, nor elucidate, the clinical course 
of infection and cholestasis. Besides vascular complications and rejection, these complications 
are however frequent and potentially severe complications after liver transplantation. In Study II, 
such complications were not at all taken into consideration. In the literature, the reported 
incidence of infection is approximately 30 %35 and biliary complications occur in approximately 
15 %.36 We have only described cases of infection and cholestasis occurring while the 
microdialysis catheters were in the liver grafts. Accordingly, several patients had infections at 
other sites, as well as suffering from infections after the catheters were removed. In order to 
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present as validated data as possible, we chose to only present data from grafts with cholestasis 
which were proven by biopsy. Accordingly, there may certainly have been cases of subclinical 
cholestasis in the reference group.  Hence, the results regarding infection and cholestasis should 
be interpreted with caution.  
In general, the number of grafts with complications is restricted, and care should be taken 
drawing any strict conclusions. In Study II the number of grafts with ischemia was particularly 
restricted, and in Study III, the number of investigated subjects is very small.  
According to the aim of Study II, pilot analyses with the 27-plex kit were exclusively 
performed in grafts with rejection. Thus, mediators likely to be important in ischemia and 
ischemia/reperfusion injury, e.g. tumor necrosis factor-α were not investigated. 
The microdialysis catheters’ life span is time-limited as the membranes become clotted by 
e.g. cellular debris. There is no possibility to predict the time-point of catheter malfunction.97 As 
shown by Wælgaard et al, the capability to recover larger proteins is restricted.98 This 
phenomenon most likely limited our possibility to investigate the effect of treatment of rejection 
other than showing the effect of treatment in only 4/12 grafts receiving anti-rejection treatment in 
Study I.  
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Main conclusions 
Study I 
x Bedside measurements of lactate and pyruvate detected ischemia and rejection 
with clinically highly acceptable levels of sensitivity and specificity.  
x Episodes of vessel occlusion were detected with intrahepatic microdialysis 
catheters while arterial lactate remained unchanged. 
x Rejection was detected several days before significant changes were observed in 
routine blood samples.  
Study II 
x CXCL-10 increased selectively in liver grafts with rejection. 
x Intrahepatic CXCL-10 increased before circulating ALT or bilirubin increased. 
x C5a was elevated selectively in ischemic grafts and was thus able to discriminate 
rejection from ischemia.  
Study III 
x The results from Study I were confirmed and ischemic vascular complications and 
rejections were detected in close to real time with clinically satisfactory levels of 
sensitivity.  
x The restricted specificity in detecting rejection urges the need for additional 
intrahepatic markers.   
x The catheters were well tolerated by the children and the method is feasible and 
safe also for this patient group.  
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Further perspectives 
As a consequence of the present studies and clinical need we have implemented 
microdialysis catheters as part of the standard postoperative monitoring of pediatric liver 
transplants. This is the patient group which is most likely to benefit from close intra organ 
monitoring because of high complication rates. Also due to somewhat high costs for the 
equipment needed it is reasonable to use it in the patients having the highest potential for 
developing resolvable complications.  
The ability for the microdialysis method to detect postoperative infections will be 
explored in ongoing and planned studies in both transplanted and not transplanted patients. 
Postoperative infections are common, and they have negative impact on survival rates, duration 
of hospital stay, as well as costs for hospitals and communities. With that in mind, the 
microdialysis method may turn out to be cost-effective. 
Microdialysis should be considered a semi continuous monitoring tool, and human 
intervention is required at a regular basis to carry out the analysis. An automatic system would be 
of benefit, but so far struggles to develop such a system including the important metabolite 
pyruvate have not succeeded.  
The relative high costs of the microdialysis system and also the technical limitations ask 
for easier and cheaper tools for intra organ monitoring. One of the main interests of research in 
our group is developing a sensor for continuous monitoring of tissue PCO2 as increasing levels of 
PCO2 measured in organs is a sensitive and specific variable to detect hypoperfusion and 
ischemia 99-105. Our hope is to develop a sensor which can do continuous readings of e.g. 
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intrahepatic PCO2 for several days. The sensor is fully automatic and does not require human 
intervention.  
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